Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: in vitro and in vivo studies.
The development of magnetic nanoparticles as delivery carriers to magnetically accumulate anticancer drug in cancer tissue has attracted immense interest. In the present study, magnetic mesoporous silica nanoparticles (MMSNs) with magnetite core and silica shell were synthesized. The obtained MMSNs were characterized by DLS, XRD, FT-IR, TEM and VSM in order to investigate the nanoparticle characteristics. With the focus on in vivo validation of such magnetic drug delivery systems, we selected epirubicin (EPI) as the drug. The anticancer properties of EPI-loaded MMSNs were evaluated in a C-26 colon carcinoma model. Alongside monitoring of drug in the tissues with animal imaging system, the tissue distribution was also determined quantitavely. The average size of MMSNs determined with TEM images was about 18.68 ± 2.31 nm. The cellular uptake test indicated that geometric mean fluorescence intensity (MFI) of cells treated with MMSN + EPI in presence of external magnetic field was increasing 27% compared with free EPI. In addition, treatment with drug-loaded MMSNs with the aid of external magnetic gradient had significantly higher inhibition efficacy towards tumor growth than the free EPI treated mice. The targeted drug delivery through external magnet-attraction using EPI-loaded MMSNs resulted in high tumor cell uptake, which leads to elimination of cancer cells effectively.